

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

CHANGE OF AUDITOR

This announcement is made by the board of directors (the “**Board**”) of ACESO Life Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

RESIGNATION OF AUDITOR

The Board hereby announces that ZHONGHUI ANDA CPA Limited (“**ZHONGHUI ANDA**”) resigned as the auditor of the Company with effect from 27 March 2024 as the Company and ZHONGHUI ANDA could not reach a consensus on the proposed audit fee for the financial year ending 31 March 2024 where fee negotiation commenced from Mid-March 2024. The proposed audit fee was determined after taking into account the business operation and scale of the Group, and the budgeted increase in the operational costs and there was no increment of audit fee since ZHONGHUI ANDA’s appointment in 2021. When evaluating the proposed audit fee, the Board considered cost containment initiatives and fee quotes from other auditors. Ultimately, consensus could not be reached after several rounds of discussion. ZHONGHUI ANDA resigned as the auditor of the Company after discussion with the Board and notified the resignation to the audit committee of the Company (the “**Audit Committee**”).

The Company has received a confirmation from ZHONGHUI ANDA, confirming that, save and except for the above, there were no other matters in relation to its resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or the Stock Exchange. The Board and the Audit Committee have confirmed that there are no disagreement or unresolved matters between the Company and ZHONGHUI ANDA, nor are they aware of any matters in relation to the resignation of ZHONGHUI ANDA that need to be brought to the attention of the Shareholders or the Stock Exchange.

As at the date of this announcement, the Board confirms that ZHONGHUI ANDA has not commenced any review or audit work on the consolidated financial statements of the Group for the year ending 31 March 2024. The Board believes that the resignation of ZHONGHUI ANDA will not have any material impact on the annual audit and the release of the annual results of the Group for the year ending 31 March 2024. The Board would like to take this opportunity to express its sincere gratitude to ZHONGHUI ANDA for its professional services rendered to the Company during the past years.

APPOINTMENT OF AUDITOR

Following the tender process of the Company and with the recommendation of the Audit Committee, the Board has resolved to appoint Moore CPA Limited (“**MOORE**”) as the new auditor of the Company to fill the casual vacancy following the resignation of ZHONGHUI ANDA with effect from 27 March 2024, and to hold office until the conclusion of the next annual general meeting of the Company.

The Audit Committee has considered a number of factors in assessing the appointment of MOORE as the new auditor of the Company, including but not limited to (i) the audit proposal of MOORE; (ii) the competence and calibre of MOORE including its audit experience; (iii) its independence from the Group and objectivity; (iv) its resources and capability including manpower and time; and (v) the Guidelines for Effective Audit Committees – Selection, Appointment and Reappointment of Auditors published by the Accounting and Financial Reporting Council; and (vi) other guidance materials issued by the Stock Exchange.

Based on the above, the Audit Committee has assessed and considered MOORE is eligible and suitable to act as the auditor of the Company.

The Board welcomes the appointment of MOORE as the new auditor of the Company.

By order of the Board
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

Hong Kong, 27 March 2024

As at the date of this announcement, the Board comprises two executive Directors, namely Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.